

Alston & Bird LLP

Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
(704) 444-1000
Fax (704) 444-1111

June 13, 2007

Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Re: U.S. Patent for *HAS-Free Formulations of Interferon-Beta*
Appl. No. 10/035,397; Filed October 25, 2001
Patent No. 6,887,462 B2; Issued May 3, 2005
Our File PP17201.003 (035784/240412)

Sir:

It is respectfully requested that a Certificate of Correction be issued for the above-identified patent, in accordance with 37 C.F.R. §1.322. This request is made in order to correct the mistakes incurred through the fault of the United States Patent and Trademark Office ("USPTO").

The mistakes appearing in the patent are set forth on the Certificate of Correction e-filed herewith. The last line of claim 75 was amended by way of Examiner's Amendment to replace "40 mm" with --20 mm--. A copy of this Examiner's Amendment, dated December 2, 2004 and mailed with the Notice of Allowance on December 9, 2004, is attached thereto.

Respectfully submitted,



Leslie T. Henry, Agent
Registration No. 45,714

LTH/dg
Attachments

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**

PATENT NO. : 6,887,462 B2

Page 1 of 1

APPLICATION NO. : 10/035,397

ISSUE DATE : May 3, 2005

INVENTOR(S) : Shirley *et al.*

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 28

Line 38: "40 mM" should read --20 mM--.

MAILING ADDRESS OF SENDER

ALSTON & BIRD LLP
Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Charlotte Office (704) 444-1000

COPY

Notice of Allowability	Application No.	Applicant(s)	
	10/035,397	SHIRLEY ET AL.	
	Examiner	Art Unit	
	Janet L. Andres	1646	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to amendment filed 14 September 2004.
2. ☒ The allowed claim(s) is/are 1-113.
3. ☒ The drawings filed on 11 April 2003 are accepted by the Examiner.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) ☐ All b) ☐ Some* c) ☐ None of the:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).
 - * Certified copies not received: _____.


Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
6. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
 - (b) ☐ Including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date 11/04
4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material
5. ☐ Notice of Informal Patent Application (PTO-152)
6. ☒ Interview Summary (PTO-413),
Paper No./Mail Date 11/30/04.
7. ☒ Examiner's Amendment/Comment
8. ☒ Examiner's Statement of Reasons for Allowance
9. ☐ Other _____.


JANET ANDRES
PRIMARY EXAMINER

Application/Control Number: 10/035,397
Art Unit: 1646

Page 2

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Leslie Henry on 30 November 2004.

The application has been amended as follows:

The claims withdrawn from consideration have been rejoined since a generic claim was found to be allowable.

In claim 61, "(IFN- β)" was replaced by --(hIFN- β)--. "40 mM" was replaced by --20 mM--.

In claim 62, "rhIFN- β " was replaced by --hIFN- β --.

In claim 75, "(IFN- β)" was replaced by --(hIFN- β)--. "40 mM" was replaced by --20 mM--.

In claim 76, "rhIFN- β " was replaced by --hIFN- β --.

The following is an examiner's statement of reasons for allowance: The calculations provided by Applicant indicate that the final ionic strength of the composition taught by the Hershenson patent is at least 44.23 mM. While the ionic strength taught by the patent need not be the preferred embodiment in order to anticipate the instant claims, what is disclosed in column

Application/Control Number: 10/035,397

Page 3

Art Unit: 1646

4 are buffer concentrations, not final ionic strengths. Hershenson does not teach final ionic strengths other than as calculated by Applicant.

Any comments considered necessary by Applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Janet L. Andres whose telephone number is 571-272-0867. The examiner can normally be reached on Monday, Tuesday, Thursday, Friday, 8:00-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached on 571-272-0961. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Janet L. Andres, Ph.D.
2 December 2004